A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial

OBJECTIVE: Insulin degludec/insulin aspart (IDegAsp) is a soluble coformulation of the novel basal analog insulin degludec (IDeg: 70%) and insulin aspart (IAsp: 30%). We compared the safety and efficacy of IDegAsp, an alternative formulation (AF) (55% IDeg and 45% IAsp), and insulin glargine (IGlar)...

Descripción completa

Detalles Bibliográficos
Autores principales: Heise, Tim, Tack, Cees J., Cuddihy, Robert, Davidson, Jaime, Gouet, Didier, Liebl, Andreas, Romero, Enrique, Mersebach, Henriette, Dykiel, Patrik, Jorde, Rolf
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041205/
https://www.ncbi.nlm.nih.gov/pubmed/21285389
http://dx.doi.org/10.2337/dc10-1905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041205/
https://www.ncbi.nlm.nih.gov/pubmed/21285389
http://dx.doi.org/10.2337/dc10-1905

Ejemplares similares